Immunglobulintherapie bei patienten nach autologer und allogener knochenmarktransplantation

Following bone marrow transplantation many patients are suffering from an impaired immunoglobulin production. Treatment with intravenous immunoglobulin has significantly reduced the incidence of infections as well as severe graft-versus-host disease during the early posttransplant period. However, no complete protection of the patients has been achieved. According to our own observations, especially patients with a decreased production of IgM antibodies seem to have an increased risk of cytome-galovirus-induced pneumonitis. During the late posttransplant period, patients with IgG subclass deficiency are at risk of acquiring gram-positive infections. However. randomized studies investigating the effect of immunoglobulin treatment during the late posttransplant phase have not yet been conducted.